These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32741023)

  • 1. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
    Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
    Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2021 Mar; 32(2):161-168. PubMed ID: 33025675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
    Dos Santos MV; Holth A; Bischof K; Davidson B
    Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
    Broner EC; Tropé CG; Reich R; Davidson B
    Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
    Davidson B; Doutel D; Holth A; Nymoen DA
    Virchows Arch; 2023 Jun; 482(6):975-982. PubMed ID: 37067588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
    Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
    Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
    Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.
    Brunetti M; Holth A; Panagopoulos I; Staff AC; Micci F; Davidson B
    Virchows Arch; 2019 Feb; 474(2):177-185. PubMed ID: 30467600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma.
    Chehover M; Reich R; Davidson B
    Virchows Arch; 2020 Aug; 477(2):249-258. PubMed ID: 31900634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma.
    Harel-Dassa K; Yedgar S; Tropé CG; Davidson B; Reich R
    Hum Pathol; 2017 Apr; 62():115-121. PubMed ID: 28087476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; Holth A; Dong HP
    Virchows Arch; 2020 Nov; 477(5):677-685. PubMed ID: 32472195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
    Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
    Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
    Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
    Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Filippov-Levy N; Cohen-Schussheim H; Tropé CG; Hetland Falkenthal TE; Smith Y; Davidson B; Reich R
    Gynecol Oncol; 2018 Mar; 148(3):559-566. PubMed ID: 29310950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble AXL is ubiquitously present in malignant serous effusions.
    Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
    Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.